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Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S327(vs. PBSC) in 146 (62%) recipients. Disease status was early,
intermediate and advanced in 98, 69 and 69 recipients,
respectively. Conditioning intensity was myeloablative (vs.
reduced intensity) in 176 (75%) recipients. GVHD prophylaxis
was MTX based, MMF based and FK in 152, 74 and 10 re-
cipients, respectively. HLA match was 8/8 and 10/10 in 184
(78%) and 179 (76%) pairs, respectively. HLA-DPB1 and MICA
were matched in 44 (19%) and 197 (85%) recipients, respec-
tively. Recipients included 137 (58%) males, 222 (94%) white.
Mean age was 4414 years.
SNPs c.2918+98G, c.3316C, and c.4385C (reference
sequence C4A NG_011638.1) were associated with severe
GVHD and analyzed as a composite variable. Mismatch at 1
of the 3 SNPs occurred in 49 pairs and 187 were matched
across all 3 SNPs. SNP mismatch was associated with
increased risk of severe GVHD in univariable analysis (HR
2.43, 95% CI 1.32-4.47, P¼0.004). There were no signiﬁcant
differences among SNP match and mismatch pairs regarding
HLA match (10/10 vs. <10/10, 8/8 vs. <8/8, DPB1), MICA
match, and patient, disease or transplant characteristics. SNP
mismatch remained signiﬁcantly associated with severe
GVHD in a multivariable analysis (HR 2.54, P¼0.002) after
adjusting for graft source, HLA and MICA mismatch.
Conclusion: GB SNPmismatch is associatedwith a higher risk
of severe acute GVHD independent of the HLA and MICA
match and other clinical risk factors. Avoiding GB SNP
mismatch can potentially reduce the risk of severe acute
GVHD and further investigation in larger cohorts is warranted.473
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Introduction: Killer-cell immunoglobulin-like receptors
(KIRs) are highly polymorphic. Donor KIR2DL1-R 245 poly-
morphism has been associated with stronger signaling
function than others. Our aim is to evaluate this donor
polymorphism in the setting of T cell-repleted haploidentical
hematopoietic stem-cell transplantation (HSCT) with post-
infusion high-dose cyclophosphamide (PiCy).
Patients and Methods: Thirty-nine adult patients who un-
derwent T-cell repleted haploidentical HSCT with PiCy in a
single center were included. Median age was 41 (r: 19-65).
Diagnosis was: Hodgkin’s Lymphoma 11 (28%), Acute
Myeloid Leukemia 14 (35%), Myelodisplastic Syndrome 3
(8%), Acute Lymphoblastic Leukemia 4 (11%), Myeloprolifer-
ative Syndromes 1 (2%), Non-Hodking Lymphoma 4 (11%),
Multiple Myeloma 2 (5%). Conditioning regimen was: mye-
loablative in 16 patients and reduced intensity in 23 patients.
The donor-patient kinshipwas: father in 5 cases (5%), mother
in 10 cases (26%), sibling in 17 cases (44%) and son/daughter
in 7 cases (18%). Donor KIR2DL1 functional allele typing was
retrospectively performed using single nucleotide poly-
morphism assay (Bari et al, Clinical Immunology 2011). KIR
genotype was analyzed by PCR (KIR Typing, Miltenyi Biotec)
using genomic DNA puriﬁed by the (Maxwell 16 Blood DNA
Kit, Promega) from peripheral blood examples. KIR ampli-
cons were visualized with ethidium bromide after agarose
gel electrophoresis. HLA typing was used to identify HLAclass I KIR ligands: HLA-C alleles with a Lys80 residue (C2
alleles), HLA-C with an Asn80 residue (C1 alleles), and HLA-B
alleles with Bw4 and Bw6 speciﬁcity.
Results: Donor KIR2DL1 polymorphismwas: KIR2DL1-R 245
homozygous 26 (66.6%), KIR2DL1-R 245/C245 13 (33,3%),
KIR2DL1-C 245 homozygous 0 (0%). Donor KIR haplotipe was
A-A in 4 (12%) and Bx in 34 (87%). Patient haplotype was A-A
in 7 (18%) and Bx in 32 (82%). Thirteen patients received a
KIR2DL1-R 245 homozygous graft with HLA-C ligand-re-
ceptor mismatch, 13 patients received a KIR2DL1-R 245 graft
with no HLA-C ligand-receptor mismatch and 12 patients
received a KIR2DL1-R 245/KIR2DL1-C245 graft. We did not
ﬁnd event free survival (EFS) differences between patients
who received a KIR2DL1-R 245 homozygous graft or a
KIR2DL1-R 245/KIR2DL1-C245 graft (67% vs 68% p¼0.37).
However, patients who received a KIR2DL1-R 245 graft with
HLA-C ligand-receptor mismatch had a marked tendency to
better event free survival (EFS) compared with those who
received a graft with KIR2DL1-R 245 and no HLA-C ligand-
receptor mismatch (80% vs 100% respectively, p¼0.057) one
year after transplant
Conclusion: Donor KIR2DL1-R 245 allelic polymorphism
associated with KIR HLA-C ligand-receptor mismatch could
affect recipient outcomes after T cell-repleted haploidentical
HSCT with PiCy. These ﬁndings could have signiﬁcant
repercussion for donor selection.474
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Chronic graft-versus-host disease (cGVHD) is a major cause
of morbidity and mortality following allogeneic hemato-
poietic stem cell transplant (AHSCT). Although current
therapies largely target T cell proliferation, in vivo T cell
kinetics of division, death and trafﬁcking have been difﬁ-
cult to evaluate. We employed deuterated water labeling
with subsequent GC-MS/MS enrichment detection to
measure in vivo T cell kinetics after AHSCT in a mouse
model of cGVHD. We investigated CD4 T cell sub-popula-
tion kinetics of cell division, death and trafﬁcking, in non-
target and target tissues of cGVHD. Early in the disease
course, spleens of AHSCT recipients showed a high number
of CD4+ T regulatory (Treg) and T effector memory (Tem)
cells. In vivo cell division kinetics of these two cell types
were high and similar to each other, and slowed as cGVHD
progressed. Meanwhile, Tem cell loss from the spleen was
signiﬁcantly faster than that of Treg cells, likely as a result
of increased trafﬁcking. In support of trafﬁcking was the
ﬁnding of elevated Tem numbers in peripheral blood of
AHSCT recipients despite a relative lymphopenia early in
the disease with subsequent disappearance from the cir-
culation once cGVHD was clinically evident. Furthermore,
overall Tem cell numbers in the host were signiﬁcantly
